Shots:  

• The OLE P-II study involves assessing of Aimovig monthly (70mg) vs PBO in 383 eligible adult patients with an episodic migraine for 12wks. 250 patients increasing their dosage to 140mg monthly after a protocol amendment to assess the long-term safety of the higher dose
• The results of the OLE study showed the therapy helped patients to achieve 5.3days reductions in MMD and 4.4 days reduction in the use of AMSM- and has the longest duration of safety and efficacy trial data for any anti-CGRP pathway therapy- will be presented at the Migraine Trust Virtual Symposium
• Amgen will also present additional studies that include interim results of the LIBERTY OLE study- as well as efficacy and safety results of Aimovig in the EMPOwER study. Aimovig is the first and only FDA and EMA-approved migraine preventive treatment targeting CGRP receptor

­ Ref: Amgen | Image: CNBC

Related News: Amgen’s Aimovig (erenumab-aooe) Receives FDA’s Approval for Prevention of Migraine in Adults